What is Nuvation Bio's market cap?

Nuvation Bio (NUVB) has a market capitalization of $2.3B and trades on NYSE.

What is Nuvation Bio's revenue and profitability?

Nuvation Bio generated $143.0M in trailing twelve-month revenue with a net loss of $146.0M, representing a net margin of -102.1%. Gross margin stands at 54.3%, with free cash flow of -$133.7M. These figures are based on the Q1 2026 filing.

Who are Nuvation Bio's competitors?

Nuvation Bio's key competitors include Nuvalent, Pfizer Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.

Who does Nuvation Bio partner with?

Nuvation Bio's notable partners include Daiichi Sankyo Company, Limited, Innovent Biologics (Suzhou) Co. Ltd., Nippon Kayaku Co., Ltd, and others.

What subsidiaries does Nuvation Bio have?

Nuvation Bio's subsidiaries include AnHeart Therapeutics Ltd., Nuvation Bio Operating Company Inc., Nuvation Bio China Ltd..

Where is Nuvation Bio headquartered?

Nuvation Bio is headquartered in United States of America and employs approximately 159 people. It has been publicly traded since 2021.

Nuvation Bio

NUVB

Nuvation Bio is a global oncology company focused on developing novel small molecule therapies for difficult-to-treat cancers.

Market cap

$2.32B+183%

Revenue$143.0M+1,206%

Net income-$146.0M+75.9%

Free cash flow-$133.7M+15.0%

EPS (diluted)-$0.43+80.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$83.2MBeat by $17.0M EPS$0.01Miss by $0.11

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$26.5M

EPS estimate-$0.15

Financials

Q1 2026

Income statement

See full

Revenue$83.2M+2,599%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation & ratios

Valuation

See full

Market cap$2.32B+183%

Enterprise value$2.25B+232%

P/S16.2×-44.2×

Profitability

See full

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Segments

By product

See full

License$64.7M+1,999%

Product Revenue$18.5M+2,213%

Royalty Revenue$1.4M+600%

Research And Development Service Revenue$700.0K-63.2%

Competitors

By market cap

Pfizer$140.61B+1.7%

Bristol-Myers Squibb$127.75B+32.1%

Immunome$2.6B+171%

Nuvation Bio$2.3B+167%

ArriVent BioPharma, Inc.$1.4B+82.9%

Inhibrx Biosciences, Inc.$1.2B+240%

Rigel Pharmaceuticals$691.8M+93.6%

Cardiff Oncology$65.0M-73.8%

By revenue growth

Nuvation Bio+1,206%

Rigel Pharmaceuticals+47.6%

Bristol-Myers Squibb+1.8%

Pfizer+1.4%

Immunome-63.3%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Pfizer15.65%+6.3pp

Bristol-Myers Squibb15.01%+3.8pp

Nuvation Bio-102.06%+5,432pp

Immunome-5,593.85%-3,719pp

Inhibrx Biosciences, Inc.-10,773.46%—

Profile

Nuvation Bio is a global oncology company focused on developing novel small molecule therapies for difficult-to-treat cancers. The company leverages medicinal chemistry expertise to target validated pathways, aiming to improve efficacy and overcome safety limitations of existing standard-of-care treatments.

Competitive position

Nuvation Bio is transitioning to a commercial-stage entity with the launch of IBTROZI, positioning itself as a developer of potential best-in-class therapies for ROS1-positive lung cancer.

GeographiesUnited States, China, Japan, European Union

Customer segmentsPatients, Pharmaceutical partners

Business modelProduct development and commercialization, Licensing and royalties

SuppliersContract Manufacturing Organizations (CMOs), Third-party API suppliers, Academic research institutions

CustomersSpecialty distributors, Hospitals, Oncology clinics, International licensing partners

CountryUnited States of America

Listed2021

Employees159.0

CEODavid T. Hung

SectorHealthcare

IndustryBiotechnology

Websitenuvationbio.com

FilingsSEC EDGAR

Ask your AI about Nuvation Bio.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's market cap?: Nuvation Bio (NUVB) has a market capitalization of $2.3B and trades on NYSE.
What is Nuvation Bio's revenue and profitability?: Nuvation Bio generated $143.0M in trailing twelve-month revenue with a net loss of $146.0M, representing a net margin of -102.1%. Gross margin stands at 54.3%, with free cash flow of -$133.7M. These figures are based on the Q1 2026 filing.
Who are Nuvation Bio's competitors?: Nuvation Bio's key competitors include Nuvalent, Pfizer Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.
Who does Nuvation Bio partner with?: Nuvation Bio's notable partners include Daiichi Sankyo Company, Limited, Innovent Biologics (Suzhou) Co. Ltd., Nippon Kayaku Co., Ltd, and others.
What subsidiaries does Nuvation Bio have?: Nuvation Bio's subsidiaries include AnHeart Therapeutics Ltd., Nuvation Bio Operating Company Inc., Nuvation Bio China Ltd..
Where is Nuvation Bio headquartered?: Nuvation Bio is headquartered in United States of America and employs approximately 159 people. It has been publicly traded since 2021.